2 terminated, 1 active not recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow Refractory Acute Biphenotypic Leukemia: new trials by email Literature Review of Refractory Acute Biphenotypic Leukemia trials Research Report on Refractory Acute Biphenotypic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 Omacetaxine Mepesuccinate, Venetoclax - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 24 | 2021-12-17 | 2025-11-03 |
| Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Decitabine and Cedazuridine, Venetoclax - Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 20 | 2021-09-29 | 2026-11-12 |
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Cytarabine, Fludarabine, Pegcrisantaspase - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-09 | 2024-12-12 |
Leukemia, Biphenotypic, Acute (3) · Leukemia, Myeloid, Acute (3) · Blast Crisis (1) · Hematologic Neoplasms (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Prolymphocytic, T-Cell (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia (3) · Leukemia, Lymphoid (3) · Leukemia, Myeloid (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Bone Marrow Diseases (2) · Carcinogenesis (1) · Cell Transformation, Neoplastic (1) · Chronic Disease (1)
venetoclax (2) · Cytarabine (1) · Esters (1) · Homoharringtonine (1) · decitabine and cedazuridine drug combination (1) · fludarabine (1)
M.D. Anderson Cancer Center (3)
United States (3)
Abhishek Maiti (1) · Courtney DiNardo, MD (1) · Tapan M Kadia (1)